Compare Regeneron Pharmaceuticals Inc (REGN) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while iShares 20 Plus Year Treasury Bond ETF trades at $81.71. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| REGN | TLT | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | — |
52-Week High | $852.03 | $92.06 |
52-Week Low | $555.51 | $81.35 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.2 with minimal daily change. Technical signals are bearish, with moving averages indicating selling pressure and oscillators neutral. Recent Treasury buyback announcements and rising global bond yields create a volatile backdrop. The ETF continues its dividend distributions, with recent payments around $0.32 per share.
Outlook remains cautious amid rising interest rate expectations and inflation concerns. Investment opportunity exists for long-term income seekers, but risks include further yield increases and potential large-scale Treasury selling by institutional investors like Norway's sovereign fund.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
